WEWON'TREST
DISEASE NEVER TAKES A BREAK,
SO NEITHER DO WE
We won’t rest until people around the world see a brighter tomorrow.
Despite its challenges, 2021 will be a year to celebrate some key milestones in medical innovation. During 2021 we will evolve the We Won’t Rest campaign, which continues to be used widely across more than 40 countries and 22 languages, to help celebrate these milestones.
Everything from Polio to HIV to Ebola to COVID-19 seemed at times unbeatable. But science and innovation always finds a way to do what was once impossible. Innovation beats impossible. For patients we are making the impossible, possible.
Making the impossible, possible!
Innovations
Within the next 5-10 years cutting edge developments in medicine will transform the lives of patients. These are the main therapy areas set to make the biggest difference.
ХЕМОФИЛИЯ А
ГОЛЯМОТО ДЕПРЕСИВНО РАЗСТРОЙСТВО
СЪРПОВИДНО-КЛЕТЪЧНАТА АНЕМИЯ
МНОЖЕСТВЕН МИЕЛОМ
ГЛИОБЛАСТОМ
МНОЖЕСТВЕНА СКЛЕРОЗА
БОЛЕСТ НА АЛЦХАЙМЕР
ДИАБЕТ
РАК НА КРЪВТА
РАК НА БЕЛИЯ ДРОБ
БАКТЕРИАЛНИ ИНФЕКЦИИ
ХЕМОФИЛИЯ Б
МИГРЕНА
ИНФЕКЦИИ
ЧЕРНОДРОБНИ ТРАНСПЛAНТАЦИИ
АМИОТРОФИЧНА ЛАТЕРАЛНА СКЛЕРОЗА
HAEMOPHILIA A
MAJOR DEPRESSIVE DISORDER (MDD)
SICKLE CELL DISEASE
MULTIPLE MYELOMA
GLIOBLASTOMA
MULTIPLE SCLEROSIS
ALZHEIMER'S DISEASE
DIABETES
BLOOD CANCER
LUNG CANCER
BACTERIAL INFECTIONS
HAEMOPHILIA B
MIGRAINES
LIVER TRANSPLANTATIONS
INFECTIONS
AMYOTROPHIC LATERAL SCLEROSIS (ALS)
My condition does not stop me from enjoying my hobby - motorcycling.
Living with Behterev's disease for 30 years
Dimitar Yanev
Thanks to the innovation in medicine, already 8 years I am living normally and I can climb mountains.
Living with Behterev's disease for 20 years
Albena Yaneva
For the chance that gives me innovation every day. For the chance to travel around the world and realize my dreams. For the chance to be here and now.
Living with chronic hepatitis B, on a long-lasting antiviral therapy
Silvana Lesidrenska
Oncohaematological diseases are not a punishment. They are a struggle, and the victory is very satisfying
In remission after treatment of Non-Hodgkin's lymphoma
Angelina Vladimirova
I want more from life, as life is in my blood, I can give more to life and have what to take from it too.
In remission after treatment of Hodgkin's lymphoma
Martin Monov
I dream of the day when cancer will be just a minor disorder.
In remission after treatment of Hodgkin's lymphoma
Marieta Stoyneva
For the chance to give patients the chance to benefit from their treatment without the severe side effects of conventional chemotherapies.
Oncologist
Charlotte
For the chance to give back portions of lost life to people.
MD specialising in neuroscience
Danny Bar-Zohar
For the chance to pursue music, pursue arts, be creative and find a new path in life
Living with T-Cell Acute Lymphoblastic Leukaemia
Jaymz Goodman
ForTheChance to become a grandmother one day
Living with metastatic breast cancer
Suzanne Leempoels
ForTheChance to take long mountain walks without the fear of stumbling and fracturing my bones
Living with Fragility Fractures caused by Osteoporosis
Hanneke Lamme Wolters
ForTheChance to use a traumatic experience as a springboard to create beautiful projects out of it
Salivary gland cancer survivor
Magali Mertens De Wilmars
Innovation in pharmacy only makes sense when the patients have access to it. #WeWontRest until the global scientific advancements are available for the Bulgarian citizens.
General Manager, AbbVie
Kiril Nikolchev, Bulgaria
In the following years the pharmaceutical industry will come up with new therapies for unmet medical needs in oncology, diabetes, haemophilia, Alzheimer, infections, liver transplantations, migraines. #WeWontRest until each Bulgarian patient has the chance to receive the best therapies.
Executive Director, ARPharM
Deyan Denev, Bulgaria
We Won’t Rest until our innovative medicines are made available to all eligible cancer patients worldwide.
President, Europe & Canada, Takeda
Giles Platford, Zurich, Switzerland
#WeWontRest until we have found a cure for Type 1 Diabetes.
Head of Europe Diabetes & Cardiovascualr Business Units, Sanofi
Marc-Antoine Lucchini, France
Director Medical Affairs Infectious Diseases, MSD.
Brand Manager, AbbVie
Karin Hagen, Sweden
#WeWontRest until we develop transformational vaccines to prevent, intercept, treat and cure life-threatening infectious diseases.
Global Head, Janssen Vaccines, Janssen
Johan Van Hoof, The Netherlands
#WeWontRest until every cancer patient can return to a normal life.
Managing Director Italy, MSD
Nicoletta Luppi, Italy
As precision medicine opens new doors in the treatment of cancer, we must overcome challenges in finding the right patient for the right treatment. #WeWontRest until patients can be considered for multiple trials on the basis of a single molecular screening.
Head of External Innovation, Merck
Dr. Joern-Peter Halle, Germany
We won't rest in research to develop new drugs that can cure diseases that still do not have effective solutions.
Head of Clinical Research, Grupo Menarini España
Isabel Paredes, Spain
#WeWontRest until hepatitis C is eliminated
Brand Manager, AbbVie
Victoria Black, UK
#WeWontRest until we live in a world in which no one suffers or dies from a vaccine-preventable disease.
General Manager, Sanofi UK, Sanofi
Hugo Fry, UK
#WeWontRest. Migraine matters and we are committed to working with the migraine community to discover new ways to improve people’s lives and give patients the voice they deserve.
Worldwide Head Neuroscience, Novartis
Lisa Deschamps
#WeWontRest until we unlock data sets all over Europe that will drive research and shape more effective patient care.
Director General, EFPIA
Nathalie Moll, Belgium
I won’t rest until patients can use their smartphones to give us trial feedback in real time.
R&D Operations Innovation Director, Janssen
Hilde Vanaken
#WeWontRest until we have the best teams working together to find new innovative therapies that help patients live longer and healthier lives.
Head of Commercial and Innovation, Roche Region Europe
Rachel Frizberg
#WeWontRest until we include patient insights in the planning of every clinical program.
Global Head Patient Affairs and Policy, Chief Medical Office, Novartis
Cathryn Clary
#WeWontRest to support and conduct clinical trials until diseases have lost their negative impact on human lives.
President (Pharmig)/ CEO (Amgen Austria), Pharmig/Amgen Austria
Martin Munte, Austria
We have advanced science and medicine to provide a cure for Hepatitis C and #WeWontRest until we have eliminated it.
Hepatitis C Brand Team Leader, AbbVie
Nuria de Diego , Spain
#WeWontRest until not one person loses their life to a vaccine-preventable illness.
Vice President Commercial Development, International Developed Markets, Pfizer
Pascale Mauran, France
#WeWontRest until we bring new advances and pioneering therapies in migraine to the patients that need them the most worldwide.
Global Head, Neuroscience Development, Novartis
Danny Bar-Zohar
#WeWontRest until health is embedded in all policies, to achieve healthier lives at all ages and stages, wherever we live.
Director General, IFPMA
Thomas B. Cueni, Switzerland
#WeWontRest until we have helped asthma patients to #LiveEveryBreath.
Respiratory Global Franchise Medical Head, GSK
Neil Barnes
#WeWontRest while opportunities exist to leverage innovative technologies to ensure the safety and wellbeing of our patients.
Pharmacovigilance Innovation Senior Specialist, Global Drug Safety & Risk Management, Celgene
Karolina Danysz
#WeWontRest in our objective to transform the way cancer is treated allowing patients to achieve better health results and better quality of life.
Oncology Head of Medical Affairs, AbbVie
Gema García Ledo, Spain
#WeWontRest in our Research efforts to bring innovative medicines that makes a real difference to all patients’ lives.
Senior Executive Vice-President Research and Development, Servier
Emmanuel Canet
#WeWontRest until we incorporate the patient voice in the treatment decision making process and ensure patients as key stakeholders.
Patient Experience Solution Lead, Immunology Patient Value Unit, UCB
Virginia Zumárraga, Spain
#WeWontRest until diagnosis becomes easier for every disease.
Value and Access Lead, Sanofi Genzyme
Walter Mei, Italy
#WeWontRest until we have helped eradicate all vaccine-preventable diseases.
SVP – Head of Research & Development, GSK Vaccines
Emmanuel Hanon
The World Health Organisation (WHO) places migraine as the top 10 of the most disabling diseases. #WeWontRest until migraine becomes a manageable condition.
Senior Director, Pain Discovery UK, Lilly
Lisa Broad, UK
#WeWontRest to ensure that our medicines, clinical trials and services meet the expectations of patients and patient organisations.
Member of the Board of Managing Directors, Boehringer Ingelheim
Allan Hillgrove, Germany
#WeWontRest until insights from individual patient experiences of living with and managing disease are built into every part of the lifecycle of our medicines and vaccines.
Group President, Innovative Health, Pfizer
John Young
#WeWontRest in our endeavor to find innovative solutions that make a difference in the lives of patients affected by serious medical conditions
Head of Research & Development, Bayer
Jörg Möller, Germany
#WeWontRest until all of the outstanding unmet need across the spectrum of SMA disease is addressed and the full impact of treatment is fully understood.
Head of Marketing SMA, Europe & Canada, Biogen
Tracy-Jane Bailey-Burnley, Switzerland
#WeWontRest until we make it possible for every eligible patient to participate in a clinical trial – irrespective their location, socio-economic status, age, mobility - and we make this participation an all-round positive experience for them.
Global Head for Trial Operations, Sanofi
Terttu Haring, The Netherlands/France
Alzheimer’s: forgetting what was so obvious before. We continue to strive to find a treatment that modifies the course of the disease and #WeWontRest until we do so.
Country Manager Belgium/Luxembourg, Lilly
Frederic Clais, Belgium
